Major double blind results announcement and scientific publication due in circa 4-5 weeks in regards to NTI’s Mente autism (neurofeedback) in-home device and its ability to calm behavioral outbursts and increase focus, vocalization, and socialization skills of children with autism.
·Multiple other milestone announcements for NTI due in the corresponding period in regards to: FDA submission, UK distributorship deal and Mente autism 2.0 (upgraded product).
· A growing clinical research base is proving neurofeedback is effective in calming the minds of children with autism. NTI has indicated positive preliminary results that Dr Ahmed Hankir of Bedforshire Centre for Mental Health Research in association with Cambridge University noted: “The Mente Autism device is one of the most exciting investigations this year…The changes observed in autistic children after a 12-week clinical trial is outstanding with many of the children scoring normal range after treatment”.
·Major United Kingdom distributorship announcement to be made in the corresponding period opening NTI to a market of 32,500 customers at a product unit price of $2865 equaling $98 million alone dependent on penetration ability. I might just add NTI has no competition in the market and its products are patented. Germany, Switzerland and Austria have a target market of 49000, Italy 30,000 and France 33,000. This does not even take into account the USA.
·The market penetration NTI is attempting to take advantage of over the next 24 months (within Europe alone is 140,000 representing up to $400,000,000 in sales.
·NTI only has a market cap of S18m – representing a small fish in a very big pond – its own pond in fact! No other ‘in-home’ neurofeedback product currently exists on the world market.
